Fig. 5

Construction of CC16-based identification model for acute exacerbation. A ROC curve was applied to calculate the diagnostic value of CC16 and KL-6 for patients with IPF. B The diagnostic value of CC16, KL-6 and DLCO-SB to distinguish AE-IPF and IPF was calculated by ROC curves. C A nomogram using CC16, KL-6 and DLCO-SB for the risk of AE-IPF occurrence was constructed. D ROC curve and AUC of the model to verify the diagnostic value. E Calibration curves of the nomogram was generated for the cohort. F DCA for the nomogram was applied to evaluate the probability of clinical utility